Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511315 · ClinicalTrials.gov registry record · Phase 4
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
A Phase 4 study of Psoriasis, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01511315 is a Phase 4 study of Psoriasis that has completed, run by University of California, San Francisco. The registered enrollment target is 36 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01511315, a Phase 4 study of Psoriasis, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.
Conditions Studied
Interventions
- DRUG Ustekinumab
Study Locations (1)
California
- UCSF Psoriasis and Skin Treatment Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511315
The ClinicalTrials.gov registry entry for NCT01511315 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (93% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Ustekinumab is the first listed.
NCT01511315 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01511315 about?
NCT01511315 is a clinical study titled "The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment". This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.
What is the current status of trial NCT01511315?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2012-03. Estimated completion is 2014-12.
What conditions does trial NCT01511315 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01511315?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT01511315?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01511315 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.